Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial

IMPORTANCE: Trastuzumab has been the standard of care for the treatment of patients with ERBB2-positive breast cancer; however, cardiac events have been reported. This long-term follow-up study provides clinical evidence supporting the similarity of a trastuzumab biosimilar (SB3) to reference trastu...

Descripción completa

Detalles Bibliográficos
Autores principales: Pivot, Xavier, Cortés, Javier, Lüftner, Diana, Lyman, Gary H., Curigliano, Giuseppe, Bondarenko, Igor M., Ahn, Jin-Hee, Im, Seock-Ah, Litwiniuk, Maria, Shparyk, Yaroslav V., Ho, Gwo Fuang, Kislov, Nikolay V., Wojtukiewicz, Marek, Sarosiek, Tomasz, Chae, Yee Soo, Ahn, Jin Seok, Jang, Hyerin, Kim, Sujung, Lee, Jiwon, Yoon, YeChan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080377/
https://www.ncbi.nlm.nih.gov/pubmed/37022687
http://dx.doi.org/10.1001/jamanetworkopen.2023.5822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080377/
https://www.ncbi.nlm.nih.gov/pubmed/37022687
http://dx.doi.org/10.1001/jamanetworkopen.2023.5822

Ejemplares similares